PE20121585A1 - ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES - Google Patents
ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USESInfo
- Publication number
- PE20121585A1 PE20121585A1 PE2012000234A PE2012000234A PE20121585A1 PE 20121585 A1 PE20121585 A1 PE 20121585A1 PE 2012000234 A PE2012000234 A PE 2012000234A PE 2012000234 A PE2012000234 A PE 2012000234A PE 20121585 A1 PE20121585 A1 PE 20121585A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- ectodominium
- Prior art date
Links
- 102000056372 ErbB-3 Receptor Human genes 0.000 title 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 201000010174 renal carcinoma Diseases 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN ANTICUERPO CONTRA ErbB3 QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 1 Y COMPRENDE UNA CDRH1 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 7, UNA CDRH2 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 8, Y UNA CDRH3 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 9; Y B) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 2 Y COMPRENDE UNA CDRL1 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 10, UNA CDRL2 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 11, Y UNA CDRL3 QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEQ ID Nº 12. TAMBIEN SE REFIERE A UN METODO DE TRATAMIENTO DE CARCINOMA RENAL, CANCER DE PROSTATA, CANCER DE OVARIO Y CANCER PULMONAR QUE COMPRENDE ADMINISTRAR EL ANTICUERPO CONTRA ErbB3 Y OTRO COMPUESTO TAL COMO ERLOTINIB, TAXOL O CISPLATINO PARA OBTENER UN EFECTO SINERGICO EN LA SUPRESION DEL CRECIMIENTO DEL TUMORIT REFERS TO AN ANTIBODY AGAINST ErbB3 WHICH INCLUDES: A) A HEAVY CHAIN VARIABLE REGION THAT HAS AN AMINO ACID SEQUENCE OF SEQ ID NO 1 AND INCLUDES A CDRH1 THAT HAS THE AMINO ACID SEQUENCE OF SEQ ID NO 7, A CDRH2 THAT HAS AMINO ACID SEQUENCE OF SEQ ID No. 8, AND A CDRH3 HAVING THE AMINO ACID SEQUENCE OF SEQ ID No. 9; AND B) A LIGHT CHAIN VARIABLE REGION THAT HAS AN AMINO ACID SEQUENCE OF SEQ ID NO. 2 AND INCLUDES A CDRL1 HAVING THE AMINO ACID SEQUENCE OF SEQ ID NO. 10, A CDRL2 HAVING THE AMINO ACID SEQUENCE OF SEQ ID NO. 11, AND A CDRL3 THAT HAS THE SEQ ID NO. 12 AMINO ACID SEQUENCE ALSO REFERS TO A TREATMENT METHOD FOR RENAL CARCINOMA, PROSTATE CANCER, OVARIAN CANCER AND LUNG CANCER THAT INCLUDES ADMINISTERING THE ANTIBODY, AS ANOTHER COMPUTER, AS ANTIBODY ERL3 TAXOL OR CISPLATINE TO OBTAIN A SYNERGIC EFFECT IN THE SUPPRESSION OF TUMOR GROWTH
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23579909P | 2009-08-21 | 2009-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20121585A1 true PE20121585A1 (en) | 2012-11-29 |
Family
ID=43607614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012000234A PE20121585A1 (en) | 2009-08-21 | 2010-08-23 | ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2467164A2 (en) |
| JP (1) | JP5752687B2 (en) |
| KR (1) | KR20120059568A (en) |
| CN (1) | CN103002912A (en) |
| AU (1) | AU2010284018C1 (en) |
| BR (1) | BR112012003809A2 (en) |
| CA (1) | CA2771744A1 (en) |
| CR (1) | CR20120108A (en) |
| DO (1) | DOP2012000044A (en) |
| EA (1) | EA201200195A1 (en) |
| EC (1) | ECSP12011740A (en) |
| IL (1) | IL218097A0 (en) |
| IN (1) | IN2012DN01518A (en) |
| MA (1) | MA33582B1 (en) |
| MX (1) | MX336091B (en) |
| NI (1) | NI201200027A (en) |
| PE (1) | PE20121585A1 (en) |
| SG (1) | SG178509A1 (en) |
| TN (1) | TN2012000057A1 (en) |
| WO (1) | WO2011022727A2 (en) |
| ZA (1) | ZA201201195B (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| TWI630916B (en) | 2009-11-13 | 2018-08-01 | 第一三共歐洲公司 | Medicine and method for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases |
| NZ600262A (en) | 2009-12-22 | 2013-06-28 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| SG183532A1 (en) | 2010-03-11 | 2012-09-27 | Merrimack Pharmaceuticals Inc | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| ES2566602T3 (en) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
| CN105037552B (en) | 2010-08-20 | 2019-03-29 | 诺华股份有限公司 | EGF-R ELISA 3(HER3) antibody |
| TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding protein |
| IT1402149B1 (en) * | 2010-10-04 | 2013-08-28 | Ist Fisioterap Ospitalroma | USE OF A PHOSPHOPEPTIDE WHICH IS ABLE TO BLOCK THE HER3 / P85 INTERACTION FOR THE TREATMENT OF HER2 EXPRESSION TUMORS. |
| KR101773120B1 (en) | 2010-11-01 | 2017-08-30 | 심포젠 에이/에스 | Anti-her3 antibodies and compositions |
| CA2833643A1 (en) | 2011-04-19 | 2012-10-26 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies |
| EP2722343A4 (en) * | 2011-06-20 | 2014-12-17 | Kyowa Hakko Kirin Co Ltd | ANTI-erbB3 ANTIBODY |
| AU2012316402B2 (en) | 2011-09-30 | 2017-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| CN108753942A (en) | 2011-10-06 | 2018-11-06 | Aveo制药公司 | Predict the response of tumour confrontation ERBB3 antibody |
| CA2855298A1 (en) * | 2011-11-09 | 2013-05-16 | The Uab Research Foundation | Her3 antibodies and uses thereof |
| KR102218497B1 (en) | 2011-12-05 | 2021-02-22 | 노파르티스 아게 | Antibodies for epidermal growth factor receptor 3 (her3) |
| WO2013124297A1 (en) * | 2012-02-22 | 2013-08-29 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| WO2015058108A1 (en) * | 2013-10-17 | 2015-04-23 | Sanford-Burnham Medical Research Institute | Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| AU2015223566B2 (en) * | 2014-02-28 | 2020-10-08 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
| CN105367657B (en) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | Anti-HER3 antibody, its preparation method and application |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| JP2017534574A (en) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | Compositions and methods for treating cancer resistant to tyrosine kinase inhibitors (TKI) |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| DK3365373T3 (en) | 2015-10-23 | 2021-04-06 | Merus Nv | BINDING MOLECULES THAT INHIBIT CANCER GROWTH |
| MX2019011660A (en) | 2017-03-31 | 2019-11-18 | Merus Nv | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene. |
| MX2019013804A (en) | 2017-05-17 | 2020-02-24 | Merus Nv | COMBINATION OF A BIESPECIFIC ANTIBODY OF ERBB-2 / ERBB-3 WITH ENDOCRINE THERAPY FOR BREAST CANCER. |
| WO2019028555A1 (en) | 2017-08-09 | 2019-02-14 | University Of Saskatchewan | Her3 binding agents and uses thereof |
| HRP20250474T2 (en) | 2017-08-09 | 2025-08-01 | Merus N.V. | Antibodies that bind egfr and cmet |
| GB201804094D0 (en) * | 2018-03-14 | 2018-04-25 | Ultrahuman Thirteen Ltd | ERBB3 Binding agents |
| US20210246223A1 (en) * | 2018-06-22 | 2021-08-12 | Crd Pharmaceuticals Inc | ANTI-HER3 Antibody and uses thereof |
| CN116133694A (en) * | 2020-10-14 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and medical application thereof |
| MX2023005940A (en) * | 2020-11-20 | 2023-07-27 | Actinium Pharmaceuticals Inc | RADIOIMMUNOTHERAPY WITH HER3 FOR THE TREATMENT OF SOLID CANCER. |
| CN117500832A (en) * | 2021-06-15 | 2024-02-02 | 北京先通生物医药技术有限公司 | anti-HER 3 antibody, antibody drug conjugate containing antibody and application thereof |
| CN119013307A (en) * | 2022-04-13 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Antibodies or antigen binding fragments thereof and medical uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579644A (en) * | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
-
2010
- 2010-08-23 PE PE2012000234A patent/PE20121585A1/en not_active Application Discontinuation
- 2010-08-23 BR BR112012003809A patent/BR112012003809A2/en not_active IP Right Cessation
- 2010-08-23 KR KR1020127007280A patent/KR20120059568A/en not_active Withdrawn
- 2010-08-23 EP EP10810721A patent/EP2467164A2/en not_active Withdrawn
- 2010-08-23 SG SG2012011664A patent/SG178509A1/en unknown
- 2010-08-23 MX MX2012002172A patent/MX336091B/en unknown
- 2010-08-23 JP JP2012525756A patent/JP5752687B2/en not_active Ceased
- 2010-08-23 AU AU2010284018A patent/AU2010284018C1/en not_active Ceased
- 2010-08-23 IN IN1518DEN2012 patent/IN2012DN01518A/en unknown
- 2010-08-23 EA EA201200195A patent/EA201200195A1/en unknown
- 2010-08-23 CA CA2771744A patent/CA2771744A1/en not_active Abandoned
- 2010-08-23 WO PCT/US2010/046364 patent/WO2011022727A2/en not_active Ceased
- 2010-08-23 CN CN2010800477186A patent/CN103002912A/en active Pending
-
2012
- 2012-02-09 TN TNP2012000057A patent/TN2012000057A1/en unknown
- 2012-02-14 IL IL218097A patent/IL218097A0/en unknown
- 2012-02-15 NI NI201200027A patent/NI201200027A/en unknown
- 2012-02-17 ZA ZA2012/01195A patent/ZA201201195B/en unknown
- 2012-02-20 DO DO2012000044A patent/DOP2012000044A/en unknown
- 2012-03-05 CR CR20120108A patent/CR20120108A/en unknown
- 2012-03-12 MA MA34684A patent/MA33582B1/en unknown
- 2012-03-21 EC ECSP12011740 patent/ECSP12011740A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2467164A2 (en) | 2012-06-27 |
| CR20120108A (en) | 2012-06-05 |
| CN103002912A (en) | 2013-03-27 |
| JP5752687B2 (en) | 2015-07-22 |
| ECSP12011740A (en) | 2013-02-28 |
| WO2011022727A3 (en) | 2013-06-27 |
| NI201200027A (en) | 2013-01-29 |
| ZA201201195B (en) | 2015-07-29 |
| MX2012002172A (en) | 2012-05-29 |
| JP2013506622A (en) | 2013-02-28 |
| IN2012DN01518A (en) | 2015-06-05 |
| MA33582B1 (en) | 2012-09-01 |
| WO2011022727A2 (en) | 2011-02-24 |
| AU2010284018A1 (en) | 2012-03-22 |
| EA201200195A1 (en) | 2012-12-28 |
| KR20120059568A (en) | 2012-06-08 |
| DOP2012000044A (en) | 2012-06-30 |
| AU2010284018B2 (en) | 2014-06-05 |
| TN2012000057A1 (en) | 2013-09-19 |
| AU2010284018C1 (en) | 2015-10-15 |
| SG178509A1 (en) | 2012-04-27 |
| MX336091B (en) | 2016-01-08 |
| IL218097A0 (en) | 2012-04-30 |
| CA2771744A1 (en) | 2011-02-24 |
| BR112012003809A2 (en) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20121585A1 (en) | ANTIBODIES AGAINST THE ERbB3 RECEPTOR ECTODOMINIUM AND ITS USES | |
| PE20180927A1 (en) | LAG-3 BINDING MOLECULES AND METHODS OF USE OF THEM | |
| EA201490369A1 (en) | METHODS OF CANCER TREATMENT USING ANTAGONISTS CONNECTING THE AXIS PD-1 AND MEK INHIBITORS | |
| AR077595A1 (en) | COMBINATION TREATMENTS | |
| EP4538372A3 (en) | Anti-trop2 antibody | |
| UA106890C2 (en) | LibreOfficeantibody to CDCP1 | |
| MX2020012799A (en) | COMPOSITION AND METHOD TO TREAT CANCER ASSOCIATED WITH EGFR MUTATION. | |
| PE20142242A1 (en) | ANTI-CD27 HUMAN ANTIBODIES, METHODS, AND USES | |
| NZ602084A (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| PE20161571A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
| NZ783685A (en) | Antibodies and conjugates thereof | |
| AR086579A1 (en) | PROTEINS OF UNION TO ANTIGEN | |
| SG10201906075VA (en) | Methods of treating cancer | |
| BR112014024017A8 (en) | METHODS FOR TREATMENT OF A TYPE OF CANCER, FOR TREATMENT OF CARCINOMA, FOR SELECTING A THERAPY AND FOR QUANTIFICATION AND HER3 INHIBITORS | |
| AR086044A1 (en) | ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME | |
| NZ592369A (en) | Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment | |
| EA032934B1 (en) | Use of a combination comprising an antibody specifically recognizing cd38 and cyclophosphamide | |
| EP3722810A3 (en) | Molecular profiling of tumors | |
| AR094849A1 (en) | COMBINED THERAPY INVOLVING DIRECTED ANTIBODIES AGAINST CLAUDINE 18.2 FOR CANCER TREATMENT | |
| NZ606195A (en) | Methods and compositions for liver cancer therapy | |
| AR065589A1 (en) | PREDICTION OF RESPONSE TO A HER INHIBITOR | |
| CY1119410T1 (en) | OPTIMIZED monoclonal antibodies against the TFPI inhibitor (TFPI) | |
| GB201114051D0 (en) | Compounds and their uses | |
| WO2011146568A8 (en) | Predicting response to a her inhibitor | |
| MX2013003076A (en) | Breast cancer therapeutics. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |